medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 5

<< Back Next >>

Ann Hepatol 2016; 15 (5)

HAV and HBV seroprevalence in 1,000 patients with chronic HCV infection in a Tertiary Care Center in São Paulo, Brazil

da Silva EF, Mazo DF, Oliveira CP, Medeiros RP, Carrilho FJ, Pessôa MG

Language: English
References: 34
Page: 691-695
PDF size: 133.74 Kb.


ABSTRACT

Background. Patients with chronic HCV infection and superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) have higher morbidity and mortality when compared with those without HCV infection. Therefore, HAV and HBV active immunization has become mandatory in this population and hence their serological markers must be determined. The aim of this study was to evaluate the prevalence of serological markers of HAV and HBV infection in patients with chronic HCV. Material and methods. One thousand chronic HCV patients at the University of São Paulo School of Medicine were evaluated for the prevalence of serological markers of HAV and HBV infection. Results. Anti-HAV IgG was positive in 92.3% of patients. When stratified by age, anti-HAV IgG was found in 61% of patients between 20-29 years, 70% on patients between 30-39 years, 85% on patients between 40-49 years, 94% on patients between 50-59 years, and in 99% on patients over 60 years of age. Anti-HBc IgG was positive in 244 patients (24%). Stratified by age, in 4.3% of patients between 20-29 years, 17% 30-39 years, 21% 40-49 years, 24% 50-59 years, and in 28% of patients over 60 years. Of the 244 anti-HBc IgG positive patients, 0.8% were HBsAg positive, 8.5% were anti-HBc IgG isolated and 16% were also anti-HBs positive. Conclusions. In conclusion, the prevalence of anti-HAV IgG was similar to the general Brazilian population. However, anti-HBc IgG was higher in our patients, when compared to general population of Western countries, emphasizing the importance of immunization programs for this population.


REFERENCES

  1. Tao YL, Tang YL, Qiu JP, Cai XF, Xen XT, Wang YX, Zhao XT. Prevalence of hepatitis C infection among intravenous drug users in Shanghai. World J Gastroenterol 2013; 19: 5320-5.

  2. Chen SL, Morgan TR. The Natural History of Hepatitis C Virus (HCV) Infection. Int J Med - Hepatitis A. Available from: http://www.who.int/mediacentre/factsheets/fs328/en/ [Cited: May 24, 2014].

  3. Redondo MPD, Almaraz A, Jiménez RVM, Santamaría A, Castro J, Torrego JC, Caro-Patón A. Comparison of two vaccination strategies against hepatitis A and B in patients with chronic hepatitis C. Rev Esp Enferm Dig 2009; 101: 265-74.

  4. Rowe IA, Parker R, Armstrong MJ, Houlihan DD, Mutimer DJ. Hepatitis A virus vaccination in persons with hepatitis C virus infection: consequences of quality measure implementation. Hepatology 2012; 56: 501-6.

  5. Cho HC, Paik SW, Kim YJ, Choi MS, Lee JH, Koh KC, Yoo BC, et al. Seroprevalence of anti-HAV among patients with chronic viral liver disease. World J Gastroenterol 2011; 17: 236-41.

  6. Villar LM, Melo MM, Calado IA, Almeida AJ, Lampe E, Gaspar AM. Should Brazilian patients with chronic hepatitis C virus infection be vaccinated against hepatitis A virus? J Gastroenterol Hepatol 2009; 24: 238-42.

  7. Shim M, Khaykis I, Park J, Bini EJ. Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination. Hepatology 2005; 42: 688-95.

  8. Saab S, Lee C, Shpaner A, Ibrahim AB. Seroepidemiology of hepatitis A in patients with chronic liver disease. J Viral Hepat 2005; 12: 101-5.

  9. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, Ferraro T, et al. Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients With Chronic Hepatitis C. N Engl J Med 1998; 338: 286-90.

  10. Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol 2013; 48: 681-8.

  11. Kramer ES, Hofmann C, Smith PG, Shiffman ML, Sterling RK. Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis. Dig Dis Sci 2009; 54: 2016-25.

  12. Buxton JA, Kim JH. Hepatitis A and hepatitis B vaccination responses in persons with chronic hepatitis C infections: A review of the evidence and current recommendations. Can J Infect Dis Med Microbiol 2008; 19: 197-202.

  13. Keeffe EB. Acute hepatitis A and B in patients with chronic liver disease: Prevention through vaccination. Am J Med 2005; 118: 21S-27S.

  14. Mattos AA, Gomes EB, Tovo CV, Alexandre CO, Remião JO. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. Arq Gastroenterol 2004; 41: 180-4.

  15. Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Ansaldi F, Durando P, et al. Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients. Liver Int 2003; 23: 12-8.

  16. Idilman R, De MN, Colantoni A, Nadir A, Van Thiel DH. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am J Gastroenterol 2002; 97: 435-9.

  17. Koff RS. Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. J Clin Gastroenterol 2001; 33: 20-6.

  18. Alberti A, Pontisso P, Chemello L, Fattovich G, Benvegnù L, Belussi F, De Mitri MS. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol 1995; 22: 38-41.

  19. Lau DT, Hewlett AT. Screening for hepatitis A and B antibodies in patients with chronic liver disease. Am J Med 2005; 118: 28S-33S.

  20. Devalle S, de Paula VS, de Oliveira JM, Niel C, Gaspar AM. Hepatitis A virus infection in hepatitis C Brazilian patients. J Infect 2003; 47: 125-8.

  21. Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol 2001; 96: 858-63.

  22. Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther 2004; 19: 715-27.

  23. Keeffe EB. Hepatitis A and B Superimposed on Chronic Liver Disease: Vaccine-Preventable Diseases. Trans Am Clin Climatol Assoc 2006; 117: 227-37.

  24. Felsen UR, Fishbein DA, Litwin AH. Low rates of hepatitis A and B vaccination in patients with chronic hepatitis C at an urban methadone maintenance program. J Addict Dis 2010; 29: 461-5.

  25. Focaccia R, da Conceição OJ, Sette H Jr, Sabino E, Bassit L, Nitrini DR, Lomar AV, et al. Estimated prevalence of viral hepatitis on the general population of the municipality of Sao Paulo, measured by plasmatic markers through samples collected from stratified, randomized and residence-based population survey. Braz J Infec Dis 1998; 2: 269-84.

  26. Liu CJ, Chen PJ. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J Gastroenterol 2014; 20: 2955-61.

  27. Taye S, Abdulkerim A, Hussen M. Prevalence of hepatitis B and C virus infections among patients with chronic hepatitis at Bereka Medical Center, Southeast Ethiopia: a retrospective study. BMC Res Notes 2014; 7: 272.

  28. Menegol D, Spilki FR. Seroprevalence of Hepatitis B and C markers at the population level in the municipality of Caxias do Sul, southern Brazil. Braz J Microbiol 2014; 44: 1237-40.

  29. Semnani S, Roshandel G, Abdolahi N, Besharat S, Keshtkar AA, Joshagani H, Moradi A, et al. HBV/HCV co-infection in Iran: a seroepidemiology based study. Pak J Biol Sci 2006; 9: 2538-40.

  30. Liaw YF. Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. J Gastroenterol 2002; 37: 65-8.

  31. Liu Z, Hou J. Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) dual infection. Int J Med Sci 2006; 3: 57-62.

  32. Ximenes RA, Pereira LM, Martelli CM, Merchán-Hamann E, Stein AT, Figueiredo GM, Braga MC, et al. Methodology of a nationwide cross-sectional survey of prevalence and epidemiological patterns of hepatitis A, B and C infection in Brazil. Cad Saude Publica 2010; 26: 1693-704.

  33. Brazil. Ministry of Health. Ordinance nº 02, January 18, 2013. Available from: http://portal.saude.gov.br/portal/saude/ gestor/area [Cited: May 24, 2014].

  34. Brazil. Ministry of Health. Departamento de Vigiliancia Epidemiológica. Informe técnico da Introdução da vacina adsorvida de Hepatite A. Julho de 2014.




2020     |     www.medigraphic.com